Listar por autor "Arasanz Esteban, Hugo"
Mostrando ítems 1-20 de 20
-
Clinical landscape of LAG-3-targeted therapy
Chocarro, Luisa
; Blanco, Ester; Arasanz Esteban, Hugo; Fernández Rubio, Leticia; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Fernández Hinojal, Gonzalo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2022)
Artículo / Artikulua 
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ... -
Cutting-edge CAR engineering: beyond T cells
Chocarro, Luisa ; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2022)
Artículo / Artikulua
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ... -
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ... -
Descubrimiento de nuevas dianas terapéuticas mediante un sistema de selección racional de líneas tumorales de cáncer de páncreas adaptadas a la inhibición de rutas de señalización
(2020) Tesis doctoral / Doktoretza tesia
Los objetivos de esta tesis son los siguientes: - Evaluar in vitro los efectos de una inhibición diferencial de cada una de las isoformas de AKT en una línea celular de adenocarcinoma de páncreas metastásico. - Caracterizar ... -
Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics
Arasanz Esteban, Hugo; Zuazo Ibarra, Miren ; Bocanegra Gondán, Ana Isabel; Gato Cañas, María; Martínez Aguillo, Maite; Morilla Ruiz, Idoia (MDPI, 2020)
Artículo / Artikulua
Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an acceleration of tumor growth associated with prompt clinical deterioration. The definitions based on radiological evaluation present ... -
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
Echaide Górriz, Míriam; Labiano, Ibone; Delgado, Marina; Fernández de Lascoiti, Ángela; Ochoa, Patricia; Garnica, Maider; Ramos, Pablo; Chocarro, Luisa ; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Piñeiro Hermida, Sergio; Morente Sancho, Pilar; Vera García, Ruth; Alsina, María; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vaccination due to their treatments, neoplastic diseases or both. To address this question, immune profiling was performed ... -
Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
Blanco, Ester; Chocarro, Luisa ; Fernández Rubio, Leticia; Bocanegra Gondán, Ana Isabel; Arasanz Esteban, Hugo; Echaide Górriz, Míriam; Garnica, Maider; Piñeiro Hermida, Sergio; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2023)
Artículo / Artikulua
Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even ... -
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy
Zuazo Ibarra, Miren ; Gato Cañas, María; Llorente, Noelia; Ibáñez-Vea, María ; Arasanz Esteban, Hugo; Kochan, Grazyna; Escors Murugarren, David (AME Publishing, 2017)
Artículo / Artikulua
Programmed cell death-1 (PD1) has become a significant target for cancer immunotherapy. PD1 and its receptor programmed cell death 1 ligand 1 (PDL1) are key regulatory physiological immune checkpoints that maintain ... -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Edwards, Carolyn J.; Sette, Angelica; Cox, Carl; Di Fiore, Barabara; Wyre, Chris; Sydoruk, Daniela; Yadin, David; Hayes, Philip; Stelter, Szymon; Bartlett, Phillip D.; Zuazo Ibarra, Miren ; García-Granda, María Jesús; Benedetti, Giovanni; Fiaska, Stratonik; Birkett, Neil R.; Teng, Yumin; Enever, Carrie; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Fernández, Gonzalo; Vera García, Ruth; Archer, Bethan; Osuch, Isabelle; Lewandowska, Martyna; Surani, Yasmin M.; Kochan, Grazyna; Escors Murugarren, David; Legg, James; Pierce, Andrew J. (Springer Nature, 2021)
Artículo / Artikulua
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ... -
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
Blanco, Ester; Silva-Pilipich, Noelia; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Procopio, Antonio; Ausín, Karina; Fernández Irigoyen, Joaquín ; Fernández Rubio, Leticia; Razquin, Nerea; Igea, Ana; Garnica, Maider; Echaide Górriz, Míriam; Arasanz Esteban, Hugo; Vera García, Ruth; Escors Murugarren, David; Smerdou, Cristian; Kochan, Grazyna (Springer Nature, 2024)
Artículo / Artikulua
Background: Previous studies have shown that functional systemic immunity is required for the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic reprogramming of immunosuppressive dysfunctional ... -
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Bocanegra Gondán, Ana Isabel; Fernandez Hinojal, Gonzalo; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María ; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla, Idoia; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019)
Artículo / Artikulua
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ... -
PD1 signal transduction pathways in T cells
Arasanz Esteban, Hugo; Gato Cañas, María; Zuazo Ibarra, Miren ; Ibáñez-Vea, María ; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David (Impact Journals, 2017)
Artículo / Artikulua
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating ... -
PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity
Gato Cañas, María; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Ibáñez-Vea, María ; Lorenzo, Laura; Fernandez-Hinojal, Gonzalo; Vera García, Ruth; Smerdou, Cristian; Martisova, Eva; Arozarena Martinicorena, Imanol; Wellbrock, Claudia; Llopiz, Diana; Ruiz, Marta; Sarobe, Pablo; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2017)
Artículo / Artikulua
PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer ... -
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
Arasanz Esteban, Hugo; Hernández, Carlos; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ... -
A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets
Blanco, Ester; Ibáñez-Vea, María ; Hernández, Carlos; Drici, Lylia; Martínez de Morentin Iribarren, Xabier; Gato Cañas, María; Ausín, Karina; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren ; Chocarro, Luisa ; Arasanz Esteban, Hugo; Fernández Hinojal, Gonzalo; Fernández Irigoyen, Joaquín ; Smerdou, Cristian; Garnica, Maider; Echaide Górriz, Míriam; Fernández Rubio, Leticia; Morente Sancho, Pilar; Ramos-Castellanos, Pablo; Llopiz, Diana; Santamaría, Enrique; Larsen, Martin R.; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2021)
Artículo / Artikulua
Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to ... -
Resistance training and clinical status in patients with postdischarge symptoms after COVID-19: protocol for a randomized controlled crossover trial 'The EXER-COVID Crossover Study'.
Ramírez Vélez, Robinson; Oteiza Olaso, Julio ; Casas Fernández de Tejerina, Juan Manuel; García Alonso, Nora; Legarra Gorgoñón, Gaizka; Oscoz Ochandorena, Sergio; Arasanz Esteban, Hugo; García Alonso, Yesenia ; Correa Rodríguez, María; Izquierdo Redín, Mikel (2022)
Artículo / Artikulua
Background: physical exercise induces a coordinated response of multiple organ systems, including the immune system. In fact, it has been proposed that physical exercise may modulate the immune system. However, the ... -
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
Hernández, Carlos; Arasanz Esteban, Hugo; Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ... -
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
Escors Murugarren, David; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Blanco, Ester; Piñeiro Hermida, Sergio; Garnica, Maider; Fernández Rubio, Leticia; Vera García, Ruth; Arasanz Esteban, Hugo; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ... -
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Vera García, Ruth (EMBO Press, 2020)
Artículo / Artikulua
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ... -
Understanding LAG-3 Signaling
Chocarro, Luisa ; Blanco, Ester; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021)
Artículo / Artikulua
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
